| The total investment in this facility is over Rs 900 crore. |
| Company sources confirmed the development but declined to reveal how much money the company had put in for setting up the centre. |
| Emerson Process Management, the business automation arm of the US-based $17.3 billion Emerson group, has been awarded the digital automation contract of the biopharmaceutical facility. |
| Emerson, the world's largest plant automation and process management company, will provide engineering design, digital automation, process management, validation, etc for the plant. |
| Emerson sources confirmed that RLS' new facility is the largest automation project in the life sciences industry in India but refused to divulge anything more. |
| The new plant with an initial capacity of 10,000 litres of mammalian cell culture and 1000 litres of microbial cell culture, will also be the first US food drug administration (US FDA) regulatory compliant bio-pharmaceutical facility in India. |
| The plant will use microbial and mammalian cell culture process to manufacture therapeutic proteins. |
| Reliance Life Sciences CEO KV Subramaniam said the commercial plant has been built with an objective to cater to in-house manufacturing requirement as well as contract manufacturing for its global clients. He, however, declined to name the global clients citing confidentiality agreements. |
| "The plant will be completed in various phases. The first phase of the manufacturing project will be completed in 2006," he added. |
| The company's pilot plant for in-house and contract research projects is already operational at the Dhirubhai Ambani Life Sciences Centre. |
| Reliance Life Sciences has zeroed in on the domains of medical biotechnology, plant biotechnology, contract research, clinical research and contract manufacturing. |
| The life sciences business lies mainly in the areas of stem cell-based therapeutic proteins, skin and tissue engineering and molecular diagnostics. These days the focus is on therapies in the treatment of thalassemia, leukaemia and sickle cell anaemia through stem cell research. |
| The Mukesh Ambani-controlled company is also setting up an animal house to conduct regulatory toxicology and preclinical efficacy studies for cell-based therapies. |
| Besides, the company is scaling up its existing stem cell-enriched umbilical cord blood repository. |
Top Section
Explore Business Standard